COVID-19 ARDS 的血管外肺水高于非 COVID-19 ARDS:PiCCOVID 研究
该研究为观察性研究,2020 年 3 月至 10 月在 3 所大学医院 ICU 纳入 60 例经跨肺热稀释监测的 COVID-19 相关 ARDS 患者,与 2018 年 12 月至 2020 年 2 月 COVID-19 疫情前连续收治的 60 例非 COVID-19 ARDS 患者比较。结果显示 COVID-19 组基线 EVLWi 更高(17(14-21)vs 15(11-19)mL/kg,p=0.03),最大 EVLWi 更高(24(18-27)vs 21(15-24)mL/kg,p=0.01),PVPI 结果类似;COVID-19 组最差氧合指数更低(81(70-109)vs 100(80-124)mmHg,p=0.02),俯卧位通气和 ECMO 使用更频繁,但最大乳酸水平及最大去甲肾上腺素剂量更低,60 天死亡率两组相似(57% vs 65%,p=0.45)。作者认为这与 COVID-19 特异性肺部炎症和严重弥漫性肺泡损伤相关,而血流动力学紊乱较少。
要点
- COVID-19 ARDS 患者基线 EVLWi 为 17(14-21)mL/kg,高于非 COVID-19 ARDS 的 15(11-19)mL/kg(p=0.03);最大 EVLWi 为 24(18-27)vs 21(15-24)mL/kg(p=0.01)。
- COVID-19 组 PVPI 结果与 EVLWi 类似,均高于非 COVID-19 组。
- 两组驱动压在基线和研究期间均相似。
- COVID-19 组最差氧合指数更低(81(70-109)vs 100(80-124)mmHg,p=0.02),俯卧位通气和 ECMO 使用更频繁。
- COVID-19 组最大乳酸水平和最大去甲肾上腺素剂量低于非 COVID-19 组;60 天死亡率两组相似(57% vs 65%,p=0.45)。
适用人群与场景
- 经跨肺热稀释监测的 COVID-19 相关 ARDS 成人患者(2020 年 3 月至 10 月,3 所大学医院 ICU)。
- 对照为非 COVID-19 ARDS 成人患者(2018 年 12 月至 2020 年 2 月疫情前连续收治)。
研究设计与关键结果
- 研究类型:观察性研究,3 所大学医院 ICU,COVID-19 ARDS 60 例 vs 非 COVID-19 ARDS 60 例。
- 驱动压在基线和研究期间两组相似。
- 基线 EVLWi:COVID-19 组 17(14-21)mL/kg vs 非 COVID-19 组 15(11-19)mL/kg,p=0.03。
- 最大 EVLWi:COVID-19 组 24(18-27)mL/kg vs 非 COVID-19 组 21(15-24)mL/kg,p=0.01。
- PVPI 结果与 EVLWi 类似。
- 最差氧合指数(PaO2/FiO2):COVID-19 组 81(70-109)mmHg vs 非 COVID-19 组 100(80-124)mmHg,p=0.02。
- COVID-19 组俯卧位通气和 ECMO 使用更频繁;最大乳酸水平和最大去甲肾上腺素剂量低于非 COVID-19 组。
- 60 天死亡率:COVID-19 组 57% vs 非 COVID-19 组 65%,p=0.45。
证据类型、等级与局限
- 证据类型:观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于 COVID-19 相关 ARDS 患者,跨肺热稀释测得的 EVLWi 和 PVPI 从病程初期即高于非 COVID-19 ARDS,可提示更严重的肺水肿和肺泡损伤,但驱动压相似。
- COVID-19 ARDS 患者氧合更差、更常需要俯卧位通气和 ECMO,但血流动力学紊乱(最大乳酸、最大去甲肾上腺素剂量)较非 COVID-19 ARDS 轻。
- 两组 60 天死亡率相似(57% vs 65%,p=0.45),提示尽管肺损伤指标更差,COVID-19 ARDS 的总体预后与非 COVID-19 ARDS 相当。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In acute respiratory distress syndrome (ARDS), extravascular lung water index (EVLWi) and pulmonary vascular permeability index (PVPI) measured by transpulmonary thermodilution reflect the degree of lung injury. Whether EVLWi and PVPI are different between non-COVID-19 ARDS and the ARDS due to COVID-19 has never been reported. We aimed at comparing EVLWi, PVPI, respiratory mechanics and hemodynamics in patients with COVID-19 ARDS vs. ARDS of other origin.
METHODS: Between March and October 2020, in an observational study conducted in intensive care units from three university hospitals, 60 patients with COVID-19-related ARDS monitored by transpulmonary thermodilution were compared to the 60 consecutive non-COVID-19 ARDS admitted immediately before the COVID-19 outbreak between December 2018 and February 2020.
RESULTS: Driving pressure was similar between patients with COVID-19 and non-COVID-19 ARDS, at baseline as well as during the study period. Compared to patients without COVID-19, those with COVID-19 exhibited higher EVLWi, both at the baseline (17 (14-21) vs. 15 (11-19) mL/kg, respectively, p = 0.03) and at the time of its maximal value (24 (18-27) vs. 21 (15-24) mL/kg, respectively, p = 0.01). Similar results were observed for PVPI. In COVID-19 patients, the worst ratio between arterial oxygen partial pressure over oxygen inspired fraction was lower (81 (70-109) vs. 100 (80-124) mmHg, respectively, p = 0.02) and prone positioning and extracorporeal membrane oxygenation (ECMO) were more frequently used than in patients without COVID-19. COVID-19 patients had lower maximal lactate level and maximal norepinephrine dose than patients without COVID-19. Day-60 mortality was similar between groups (57% vs. 65%, respectively, p = 0.45). The maximal value of EVLWi and PVPI remained independently associated with outcome in the whole cohort.
CONCLUSION: Compared to ARDS patients without COVID-19, patients with COVID-19 had similar lung mechanics, but higher EVLWi and PVPI values from the beginning of the disease. This was associated with worse oxygenation and with more requirement of prone positioning and ECMO. This is compatible with the specific lung inflammation and severe diffuse alveolar damage related to COVID-19. By contrast, patients with COVID-19 had fewer hemodynamic derangement. Eventually, mortality was similar between groups.
TRIAL REGISTRATION NUMBER AND DATE OF REGISTRATION: ClinicalTrials.gov (NCT04337983). Registered 30 March 2020-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT04337983 .
参考来源
- Shi R, Lai C, Teboul JL, et al. COVID-19 ARDS is characterized by higher extravascular lung water than non-COVID-19 ARDS: the PiCCOVID study. Crit Care. 2021. PMID: 34074313. doi:10.1186/s13054-021-03594-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。